Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shannon Garitty

Interventional Pain Medicine Waco, TX Medical Doctor

NPI 1629414065 CMS profile 119401

205 Woodhew Dr Ste 220, Waco, TX 76712

Open in the dashboard

General payments

$92,417

1,042 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shannon Garitty of Waco, TX is reported in the CMS Open Payments database as having received $92,417 across 1,042 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $30,638 120
2024 General $30,756 173
2023 General $3,690 148
2022 General $5,728 226
2021 General $5,430 225
2020 General $3,151 111
2019 General $13,025 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shannon Garitty
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Shannon Garitty were reported at $30,638. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Shannon Garitty Interventional Pain Medicine median Middle half National median
2019 $13,025 $684 $216–$2,079 $163
2020 $3,151 $382 $122–$1,109 $114
2021 $5,430 $552 $167–$1,554 $132
2022 $5,728 $605 $187–$1,924 $149
2023 $3,690 $671 $195–$1,915 $160
2024 $30,756 $684 $206–$1,837 $164
2025 $30,638 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. SurGenTec $38,311 11 payments
  2. Abbott Laboratories $32,583 739 payments
  3. Medtronic USA, Inc. $10,055 4 payments
  4. Nevro Corp. $2,486 25 payments
  5. Boston Scientific Corporation $1,705 45 payments
  6. Foundation Fusion Solutions, LLC $1,507 13 payments
  7. Relievant Medsystems, Inc. $1,088 19 payments
  8. Stryker Corporation $1,038 6 payments
  9. Spinal Simplicity, LLC $792 50 payments
  10. Curonix LLC $754 51 payments
  11. Other $2,095 79 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $33,588 12 payments
  2. Food and Beverage $27,596 1,003 payments
  3. Travel and Lodging $10,409 17 payments
  4. Grant $10,000 2 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $6,300 5 payments
  6. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,075 2 payments
  7. Education $450 1 payment
Products named General payments · program years 2019–2025
  1. ION Orthopedic $20,103 4 payments
  2. TiLink Orthopedic $20,103 4 payments
  3. TiLink Device $11,854 4 payments
  4. PROCLAIM Neuromodulation $11,513 263 payments
  5. SYNCHROMED $10,000 2 payments
  6. PROCLAIM Structural Heart $9,073 18 payments
  7. Ion Device $6,355 3 payments
  8. Proclaim IPG $3,969 155 payments
  9. Senza Spinal Cord Stimulation System $2,486 25 payments
  10. Proclaim Family of SCS IPGs $1,680 56 payments
  11. Other $16,604 573 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

2,813

Median for Anesthesiology: 322

Drug cost

$70,550

Median for Anesthesiology: $8,738

Branded share of claims

54.7%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,106 $33,157
Pregabalin Generic 359 $7,045
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 218 $6,875
Buprenorphine Generic 24 $6,258
Acetaminophen-Codeine Acetaminophen With Codeine Brand 155 $2,657
Gabapentin Generic 166 $2,384
Lidocaine Generic 17 $2,378
Tramadol Hcl Generic 187 $2,044
Tizanidine Hcl Generic 95 $1,350
Methocarbamol Generic 66 $1,079

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$392,815

Of which drugs: $9,916

Medicare patients

810

Average age 68

Services billed

6,561

471 women, 339 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 41%
Depression 29%
Chronic kidney disease 26%
Ischemic heart disease 25%
COPD 20%
Heart failure 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg J7329 Office 28 976 $5,408
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 94 1,290 $112
Injection, ketorolac tromethamine, per 15 mg J1885 Office 19 72 $36
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 24 36 $10

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BELBUCA
  • Collegium Pharmaceutical, Inc. $22
$22 — —
UBRELVY
  • AbbVie, Inc. $17
$17 — —
QULIPTA
  • AbbVie, Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

1,042 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record